A5083455325- Endometrial and Cervical Cancer Treatments
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Sarcoma Diagnosis and Treatment
- Electronic Health Records Systems
- Cancer Treatment and Pharmacology
- Angiogenesis and VEGF in Cancer
- Heat shock proteins research
- Radiopharmaceutical Chemistry and Applications
- ATP Synthase and ATPases Research
- Cervical Cancer and HPV Research
- HER2/EGFR in Cancer Research
- Uterine Myomas and Treatments
- Advanced Breast Cancer Therapies
- Ferroptosis and cancer prognosis
Peking University People's Hospital
2024-2025
Peking University
2020-2025
Peking University Cancer Hospital
2020
Chinese Academy of Medical Sciences & Peking Union Medical College
2019
3544 Background: CECs and CPCs are being evaluated as generic biomarkers of antiangiogenic therapy in cancer patients (pts). We hypothesized that: 1. CEC CPC kinetics depend on the agent used; 2. have differential biomarker value. Methods: Using a standard flow cytometry protocol, we measured fraction cells with phenotype among blood mononuclear at multiple time-points during treatment 4 phase 2 studies anti-VEGF agents: sunitinib hepatocellular carcinoma (HCC); cediranib glioblastoma (GBM);...
14522 Background: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor that shows significant antitumor activity in renal cell carcinoma (RCC) and other cancers. This study assessed the maximum tolerated dose (MTD), safety pharmacokinetic (PK) profile of SU combination with G advanced solid tumor pts. Methods: Pts received escalating doses (25–50 mg/day) on a 6-week (wk) cycle (4 wks on, 2 off treatment; 4/2 schedule) (750–1250 mg/m2) IV over 30 min Days 1, 8, 22, 29....
Objective The International Federation of Gynecology and Obstetrics (FIGO) released a new staging for endometrial cancer (EC), which revised the FIGO2009 to include histopathological molecular features. purpose this study was validate prognostic accuracy discuss its clinical applicability. Methods In single-centre retrospective study, 540 patients with primary surgically treated early-stage EC were enrolled staged according FIGO2009/2023. Kaplan-Meier survival analysis used compare...
Endometrial cancer (EC) is the most common gynecologic cancer. Unfortunately, its prognosis remains poor due to limited screening and treatment options. To address this issue, present study evaluated predictive value of four immunohistochemical (IHC) indicators for overall survival (OS) recurrence-free (RFS) in patients with EC. A total 834 diagnosed EC were included at Peking University People's Hospital between January 2006 December 2020. These randomly divided into training validation...
Abstract To analyze the correlation of level serum heat shock protein 90α (HSP-90α) in healthy and breast cancer patients, studying evaluation neoadjuvant efficacy Clinical value relapse monitoring. A total 102 women were selected, 51 cases benign tumor ,423 female all diagnosed by pathology,other system malignancies 62 cases. ALL samples HSP-90αwas detected double-antibody ELISA. The CEA, CA125,CA15-3 Roche Cobas ECL analyzer. ROC curve was used to effectiveness HSP-90α early diagnosis...
Abstract Background: Metastatic breast cancer remains an incurable disease, and clinical benefit progression-free survival are the main end points in advanced setting. Targeted therapies have shown promising potentials HER2-positive cancer, but with uncertain effects HER2-negative especially when disease is progressing rapidly. The regimen of antiangiogenic therapy combination chemotherapy had been studied for years gained improved efficacy. Apatinib oral, highly potent tyrosine kinase...